A double-blind placebo-controlled study to evaluate endometrial safety and gynaecological symptoms in women treated for up to 5 years with tamoxifen or placebo – A substudy for IBIS I Breast Cancer Prevention Trial



: A substudy for IBIS I Breast Cancer Prevention Trial

: Palva T, Ranta H, Koivisto AM, Pylkkänen L, Cuzick J, Holli K

Publisher: ELSEVIER SCI LTD

: 2013

: European Journal of Cancer

: EUROPEAN JOURNAL OF CANCER

: EUR J CANCER

: 1

: 49

: 1

: 45

: 51

: 7

: 0959-8049

DOI: https://doi.org/10.1016/j.ejca.2012.06.015


Conclusions: The discontinuation rate in the TAM group was high, and the discontinuations also occurred early. Even though there were significantly more non-serious gynaecological events during the TAM treatment, routine gynaecological follow-up cannot be recommended. (C) 2012 Elsevier Ltd. All rights reserved.



Last updated on 2024-26-11 at 21:27